Clinical Trial Update: A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating famitinib plus docetaxel in patients with advanced non-squamous non-small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Famitinib (Famitinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Status: COMPLETED